SCHEMBL5165767

SCHEMBL5165767

CC(=O)N(c1c(-c2ccccn2)nc2cc(C)ccn12)C1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.56
SMN1; SMN2 Q16637 6/20 0.56
LMNA P02545 5/20 0.56
ALDH1A1 P00352 5/20 0.56
HTT P42858 4/20 0.56
GFER P55789 3/20 0.56
KMT2A Q03164 5/20 0.48
NPSR1 Q6W5P4 4/20 0.48
TDP1 Q9NUW8 3/20 0.48
MITF O75030 1/20 0.48
MAPT P10636 5/20 0.47
POLB P06746 2/20 0.47
TP53 P04637 2/20 0.46
MEN1 O00255 2/20 0.43
L3MBTL1 Q9Y468 2/20 0.43
USP2 O75604 1/20 0.43
PPP1CA P62136 1/20 0.43
TRPM8 Q7Z2W7 2/20 0.41
CGAS Q8N884 1/20 0.40
MAPK1 P28482 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5168739 0.85 ALDH1A1 (0.43) GAASMN1; SMN2LMNAALDH1A1HTT
Hydrochloric Acid SCHEMBL5166037 0.83 LMNA (0.45) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5166991 0.83 ALDH1A1 (0.54) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5164734 0.82 GAA (0.46) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5165861 0.81 ATM (0.41) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5164712 0.81 MAPT (0.44) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5168630 0.81 ALDH1A1 (0.56) GAASMN1; SMN2LMNAALDH1A1GFER
SCHEMBL5168273 0.79 GAA (0.57) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL6748606 0.77 MGLL (0.38) GAASMN1; SMN2LMNAALDH1A1HTT
SCHEMBL5166774 0.75 SLC2A1 (0.35) GAASMN1; SMN2LMNAALDH1A1GFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040023972-A1 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS GRUENENTHAL GMBH (DE) 2004-02-05 US claimed
EP-1326613-B2 USE OF SUBSTITUTED IMIDAZO 1,2-A|PYRIDINE-, IMIDAZO ¬1,2-A|PYRIMIDINE AND IMIDAZO ¬1,2-A|PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS GRUENENTHAL GMBH (DE) 2007-04-18 EP disclosed
EP-1326613-B1 USE OF SUBSTITUTED IMIDAZO 1,2-A]PYRIDINE-, IMIDAZO [1,2-A]PYRIMIDINE AND IMIDAZO [1,2-A]PYRAZINE-3-YL-AMINE DERIVATIVES FOR PRODUCING NOS-INHIBITING MEDICAMENTS GRUENENTHAL GMBH (DE) 2004-06-02 EP disclosed
US-20040023972-A1 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS GRUENENTHAL GMBH (DE) 2004-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040023972-A1 Use of substituted imidazo[1,2-a]-pyridin-, -pyrimidin-and-pyrazin-3-yl-amine derivatives in the preparation of medicaments for inhibiting NOS NOS1, PTGIS, NOS2 GAA 536/4885SMN1; SMN2 59/4885LMNA 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.